Emergent Biosolutions (NYSE:EBS) Releases Earnings Results, Misses Expectations By $0.54 EPS

Emergent Biosolutions (NYSE:EBS) released its earnings results on Thursday. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing the consensus estimate of $0.11 by ($0.54), FiscalAI reports. The business had revenue of $148.70 million for the quarter, compared to analyst estimates of $217.50 million. Emergent Biosolutions had a net margin of 9.62% and a return on equity of 20.85%.

Here are the key takeaways from Emergent Biosolutions’ conference call:

• Strong 2025 financial recovery: Adjusted EBITDA of $205M (up 12% YoY), adjusted EPS of $1.53 (versus a loss in 2024), gross margin +900 bps, and operating expenses down $140M, demonstrating material margin expansion and profitability improvement.
• 2026 guidance is more conservative: Revenue guided to $720M–$760M and adjusted EBITDA to $135M–$155M (reflecting the absence of a one‑time $60M international order in 2025), and the company still expects a GAAP net loss for 2026.
• International MCM momentum and major contract wins: International sales now ~34% of MCM revenue with new multi‑year Canadian agreements (~CAD 140M) and deliveries to 20+ countries, positioning international growth as a key driver.
• NARCAN franchise updates — product and market positioning: The company maintained market leadership, won FDA approval for 6‑ and 24‑count multi‑packs and is launching a consumer carrying case, but Q4 commercial demand was temporarily softened by the U.S. government shutdown.
• Deleveraging and capital returns: Ended 2025 with $205M cash ($305M liquidity), repaid $110M gross debt (including a $100M term‑loan prepayment), repurchased shares and bonds, and approved a new $50M buyback authorization.

Emergent Biosolutions Stock Performance

Emergent Biosolutions stock traded down $2.91 during mid-day trading on Friday, hitting $8.19. 2,782,523 shares of the company’s stock traded hands, compared to its average volume of 878,323. The firm has a 50 day simple moving average of $11.76 and a two-hundred day simple moving average of $10.40. The company has a debt-to-equity ratio of 1.14, a current ratio of 5.76 and a quick ratio of 3.15. The stock has a market cap of $430.14 million, a price-to-earnings ratio of 6.33 and a beta of 2.35. Emergent Biosolutions has a fifty-two week low of $4.02 and a fifty-two week high of $14.06.

Insider Activity at Emergent Biosolutions

In related news, Director Ronald Richard sold 21,984 shares of the firm’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $11.97, for a total value of $263,148.48. Following the transaction, the director owned 98,417 shares in the company, valued at approximately $1,178,051.49. This trade represents a 18.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Emergent Biosolutions

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. CANADA LIFE ASSURANCE Co purchased a new position in shares of Emergent Biosolutions in the 4th quarter worth about $45,000. Legal & General Group Plc bought a new stake in shares of Emergent Biosolutions during the second quarter valued at about $31,000. Raymond James Financial Inc. purchased a new stake in Emergent Biosolutions in the 2nd quarter worth approximately $53,000. Kemnay Advisory Services Inc. purchased a new position in Emergent Biosolutions during the fourth quarter worth about $107,000. Finally, Abel Hall LLC bought a new position in shares of Emergent Biosolutions in the fourth quarter worth approximately $129,000. 78.40% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Wall Street Zen raised Emergent Biosolutions from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 30th. Weiss Ratings reissued a “hold (c-)” rating on shares of Emergent Biosolutions in a research report on Monday, December 29th. Finally, HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Emergent Biosolutions in a research report on Tuesday, December 16th. One research analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $15.00.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.